Leier C V, Alvarez R J, Binkley P F
Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.
Cardiology. 2000;93(1-2):56-69. doi: 10.1159/000007003.
Congestive heart failure (CHF), one of the few cardiovascular conditions increasing in incidence and prevalence, is characterized by high morbidity and mortality. Up to 50% of the mortality is attributable to dysrhythmic sudden death. Risk stratification to identify those most susceptible to sudden death remains imperfect. The advances in CHF therapeutics and management over the past 16 years have had a favorable impact on CHF mortality including sudden death. The role of amiodarone and implantable cardioverter-defibrillator intervention is evolving and discussed in the context of current CHF management and available trials.
充血性心力衰竭（CHF）是少数发病率和患病率呈上升趋势的心血管疾病之一，其特点是高发病率和高死亡率。高达50%的死亡率归因于心律失常性猝死。用于识别最易发生猝死人群的风险分层仍不完善。在过去16年中，CHF治疗和管理方面的进展对包括猝死在内的CHF死亡率产生了有利影响。在当前CHF管理和现有试验的背景下，胺碘酮和植入式心脏复律除颤器干预的作用正在不断演变并得到讨论。
